This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Marjorie A. Bowman, MD, MPA
Philadelphia, Pa

Julienne K. Kirk, PharmD; Robert Michielutte, PhD; John S. Preisser, PhD
Winston-Salem, NC

Arch Intern Med. 1997;157(11):1264-1265.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

F is a chronic and debilitating hallmark of the chronic fatigue syndrome, which is often accompanied by sleep disturbances, myalgias, and depression.^1,2 This condition has been reported worldwide, and case definitions have been developed by the Centers for Disease Control and Prevention.³ Amantadine hydrochloride has been used to treat fatigue associated with conditions such as multiple sclerosis.^4-6 We investigated the symptomatic effects of amantadine on 4 patients with chronic fatigue syndrome using a multiple single-subject trial design.⁷ Patients who had a diagnosis of chronic fatigue made by their family physicians and who fulfilled the criteria for chronic fatigue syndrome defined by the Centers for Disease Control and Prevention were included.³ Using a multiperiod, crossover design,⁸ with a single subject for each sequence, patients received either placebo (B) or amantadine hydrochloride (A), 100 mg twice daily. Patients were blinded to treatment identification.

Varying the treatment . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?